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ABSTRACT
Objective Morbidity and mortality due to heart failure 
(HF) as a complication of myocardial infarction (MI) is 
high, and remains among the leading causes of death and 
hospitalisation. This study investigated the association 
between family history of MI with or without HF, and the 
risk of developing HF after first MI.
Methods Through nationwide registries, we identified 
all individuals aged 18–50 years hospitalised with first 
MI from 1997 to 2016 in Denmark. We identified 13 810 
patients with MI, and the cohort was followed until HF 
diagnosis, second MI, 3 years after index MI, emigration, 
death or the end of 2016, whichever occurred first. HRs 
were estimated by Cox hazard regression models adjusted 
for sex, age, calendar year and comorbidities (reference: 
patients with no family history of MI).
Results After adjustment, we observed an increased 
risk of MI- induced HF for those having a sibling with MI 
with HF (HR 2.05, 95% CI 1.02 to 4.12). Those having 
a sibling with MI without HF also had a significant, but 
lower increased risk of HF (HR 1.39, 95% CI 1.05 to 
1.84). Parental history of MI with or without HF was not 
associated with HF.
Conclusion In this nationwide cohort, sibling history of 
MI with or without HF was associated with increased risk 
of HF after first MI, while a parental family history was 
not, suggesting that shared environmental factors may 
predominate in the determination of risk for developing HF.
IntROduCtIOn
Despite significant improvements in the 
management of acute myocardial infarction 
(MI) and heart failure (HF), morbidity and 
mortality due to HF as a complication of 
MI remains high, and is one of the leading 
causes of hospitalisation and death.1–3 There-
fore, the identification of individuals who are 
at a high risk of HF after MI represents a key 
public health necessity. Progression to HF 
post- MI is likely multifactorial, and includes 
environmental risk factors, comorbidities 
and genetic factors.4–7 For example, while a 
similarly sized MI and a comparable exposure 
to high blood pressure may lead to an effec-
tive compensatory response in some patients, 
a particular constellation of risk factors may 
result in HF in others. Genetic susceptibility 
factors, environmental exposures and lifestyle 
factors that contribute to HF susceptibility 
post- MI are shared within families. Previous 
studies have suggested a familial aggregation 
of HF.8–10 While this previous finding suggests 
that inherited susceptibility may contribute 
to the development of HF post- MI, with the 
exception of one study,8 previous studies did 
not distinguish between different causes of 
HF with consequent aetiological heteroge-
neity. We therefore aimed to determine the 
association between family history of MI with 
or without HF and the risk of developing HF 
after a first- time MI in the young (18–50 years 
of age). This is to our knowledge, the first 
nationwide study to examine whether a family 
history of MI with or without HF is associated 
with HF among young patients with MI.
MethOds
data sources
A unique and permanent personal identi-
fication number is assigned to all residents 
in Denmark. This number is used in all 
Key questions
What is already known about this subject?
 ► Morbidity and mortality due to heart failure (HF) as 
a complication of myocardial infarction (MI) is high, 
and remains among the leading causes of death and 
hospitalisation.
 ► It is unknown if a family history of HF after MI is a 
risk factor for HF post- MI.
What does this study add?
 ► We demonstrate that having a sibling with MI with 
or without HF was an independent risk factor for de-
veloping HF after MI, while a parental family history 
of MI with or without HF was not.
how might this impact on clinical practice?
 ► Family history of MI with or without HF, regardless 
of the nature of the various genetic and environ-
mental factors involved, serves to identify high- risk 
individuals and families for intervention to prevent 
HF post- MI.
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Figure 1 Study population selection. HF, heart failure; MI, 
myocardial infarction.
Danish health and administrative registries, and enables 
individual- level linkage between all nationwide registries. 
In this study, we combined data from four large Danish 
registries: 1) The Danish Civil Registration System which 
contains daily changes in the vital status of all residents, 
where no historical data are deleted11; 2) The Danish 
National Patient Registry which holds information on all 
admissions to hospitals since 1978, and outpatient visits 
since 1995, coded according to the International Classi-
fication of Diseases (ICD)-8 and ICD-1012; 3) The Danish 
Fertility Registry which contains data on almost all 
parents of children born in Denmark since 1954 and 4) 
The Danish Registry of Medical Product Statistics, where 
all prescriptions dispensed from Danish pharmacies have 
been registered since 1995. Each drug is coded according 
to the international Anatomical Therapeutic Chemical 
(ATC) classification system, and the registry includes data 
on type of drug, strength, quantity dispensed and date of 
dispensing,13 which has been shown to be accurate.14
study population
The study population comprised all Danish patients aged 
18–50 years hospitalised with a first- time MI (ICD-10 
code I21 or I22: ICD-8 code 410) between 1997 and 2016. 
Patients with a prior HF diagnosis (ICD-10 code I42, I50, 
I110, I130, I132 or J819: ICD-8 code 425, 428, 4270, 4271) 
were excluded. Using the Danish Fertility Database, we 
identified all first- degree relatives and collected informa-
tion on family relationship (mother, father and siblings). 
Only patients with at least one identifiable first- degree 
relative (father, mother or sibling) were included.
Family history
For each individual that was identified with a first MI 
(index MI) (age 18–50 years), we identified first- degree 
relatives (aged 18–80 years) with MI with or without HF 
occurring at a date prior to the MI index date (figure 1). 
We defined MI with HF as new onset of HF within 3 years 
from index MI, and MI without HF if the patient did not 
develop HF in this time period. If no relative was registered 
as having MI with HF or MI without HF, the person was 
considered not to have a family history of MI. We subdi-
vided the study population into three groups according 
to the family history: 1) family history of MI with HF, 2) 
family history of MI without HF and 3) no family history 
of MI. Persons with more than one first- degree relative, 
were still classified as having a family history of MI with 
HF if they had at least one family member with MI and 
HF. Family history was further stratified by the family 
relationship (father, mother or sibling). We additionally 
analysed whether the risk was similar for patients with a 
young family member (≤50 years at MI) or an old family 
member with MI with or without HF (51–80 years).
Comorbidities
Patients were considered to have certain comorbidity if 
they had at least one hospitalisation registered for that 
comorbidity before admission for the index MI. Because 
patients with hypertension (HT) and diabetes (DM) 
were not necessarily admitted to hospital with these 
specific diagnoses, these comorbidities were defined by 
either hospital diagnosis or drug prescription. HT was 
defined by treatment with ≥2 of the following classes of 
antihypertensive drugs: α-adrenergic blockers, diuretics, 
vasodilators, β-blockers, calcium channel blockers and 
renin- angiotensin system inhibitors. History of DM was 
additionally identified by at least one prescription for 
glucose- lowering drugs (ATC code A10). Details on ICD 
and ATC codes used to classify patients with comorbidity 
are listed in the online supplementary tables 1 and 2.
study outcome
The study population was followed from the date of index 
MI until the diagnosis of HF, hospitalisation with second 
MI, date of emigration or death during a maximum of 3 
years from the index MI or till study end at 31 December 
2016, whichever occurred first. In a sensitivity analysis, we 
combined the diagnosis of HF and death, as a proxy for 
a fatal MI.
statistical analyses
Baseline characteristics are presented by use of propor-
tions for categorical variables and means±SD for contin-
uous variables. Test for differences between the strata 
was done by Kruskal- Wallis test for continuous varia-
bles and by χ2 test for discrete variables. We produced 
cumulative incidence curves for HF stratified by family 
history (figures 2–3) as a competing risk using the Aalen- 
Johansen method. Grey tests were used to analyse unad-
justed differences. Cox proportional hazard regression 
models were used to obtain HRs for HF and HF combined 
with fatal MI, patients with no family history were used 
as the reference group. The adjusted Cox regression 
models included sex, age groups (18–35 and 36–50 years 
of age), calendar year (1997–2001, 2002–2006, 2007–
2011 and 2012–2016), HT and DM. The proportional 
hazard assumptions were verified through examination 
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Figure 2 (A–C) Cumulative incidence for heart failure (HF), with death and second myocardial infarction (MI) as competing 
risk stratified by family history (FHx). FHx was defined as MI aged 18–80 years (A), as MI aged 18–50 years (B) and as MI aged 
51–80 years (C).
of Schoenfeld residuals plots. For all analyses, a p value of 
<0.05 was considered statistically significant. All analyses 
were performed using SAS software, V.9.4 (SAS Institute, 
Cary, North Carolina, USA), and R V.3.4.
Results
Family history of MI with or without hF
We identified 13 810 patients aged 18–50 years with first- 
time MI hospitalisation between 1997 and 2016, without 
previous HF hospitalisation, and with ≥1 identifiable first- 
degree relative. Figure 1 shows the flow chart of the study 
population. Of these identified index cases, at inclusion, 
470 (3%) had a family history of MI with HF, 3439 (25%) 
had a family history of MI without HF and the remaining 
9901 (72%) had no family history of MI.
Clinical characteristics
Table 1 shows the baseline characteristics of the index 
cases at study inclusion stratified by family history. 
Overall, there was a male predominance in all groups 
and significant more males had a family history of MI. 
Patients with a family history of MI with or without HF 
were older (mean age 45 and 44 years vs 42 years) and 
had more HT (24% and 21%, respectively), DM (12% 
and 10%, respectively) and a higher use of statins (20% 
and 17%, respectively) compared with patients without 
any family history of MI (19%, 8% and 12%).
Incidence of hF after first MI
A total of 1324 patients (10%) were diagnosed with HF 
during the follow- up period (mean follow- up 1.7 years). The 
mean time of HF diagnosis after index MI was 74 days. The 
cumulative incidence of HF after first MI was 11.1% (95% 
CI 8.3 to 14.0), 10.1% (95% CI 9.1 to 11.1) and 9.5% (95% 
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Figure 3 (A–C) Cumulative incidence for heart failure 
(HF) and fatal myocardial infarction (MI), with second MI as 
competing risk, stratified by family history (FHx). FHx was 
defined as MI aged 18–80 years (A), as MI aged 18–50 years 
(B) and as MI aged 51–80 years (C).
Table 1 Baseline characteristics of the study population (n=13 810)
Variable Total (n=13 810) FHx of MI with HF (n=470) FHx of MI without HF (n=3439)
No FHx
(n=9901) P value
Sex, male, n (%) 10 344 (74.9) 350 (74.5) 2662 (77.4) 7332 (74.1) <0.001
MI age, mean (SD) 42.8 (5.7) 44.6 (4.2) 43.8 (4.9) 42.4 (6.0) <0.0001
Age group (years), n (%)
  18–35 1649 (11.9) 23 (4.9) 254 (7.4) 1372 (13.9) <0.0001
  36–50 12 161 (88.1) 447 (95.1) 3185 (92.6) 8529 (86.1)
Calendar year, n (%)
  1997–2001 2316 (16.8) 76 (16.2) 567 (16.5) 1673 (16.9) 0.977
  2002–2006 3924 (28.4) 135 (28.7) 964 (28.0) 2825 (28.5)
  2007–2011 3838 (27.8) 131 (27.9) 976 (28.4) 2731 (27.6)
  2012–2016 3732 (27.0) 128 (27.2) 932 (27.1) 2672 (27.0)
HT, n (%) 2637 (19.1) 113 (24.0) 733 (21.3) 1791 (18.1) <0.0001
Statin use, n (%) 1848 (13.4) 96 (20.4) 589 (17.1) 1163 (11.7) <0.0001
DM, n (%) 1214 (8.8) 55 (11.7) 329 (9.6) 830 (8.4) 0.008
Kidney disease, n (%) 441 (3.2) 13 (2.8) 101 (2.9) 327 (3.3) 0.499
AF, n (%) 239 (1.7) 4 (0.9) 46 (1.3) 189 (1.9) 0.029
PVD, n (%) 215 (1.6) 7 (1.5) 65 (1.9) 143 (1.4) 0.190
Valve disease, n (%) 152 (1.1) 7 (1.5) 33 (1.0) 112 (1.1) 0.505
AF, atrial fibrillation; DM, diabetes; FHx, family history; HT, hypertension; MI, myocardial infarction; PVD, peripheral vascular disease.
CI 8.9 to 10.1) in patients with a family history of MI with 
HF, MI without HF and no family history of MI, respectively, 
as illustrated in figure 2A. Family history was further strat-
ified by the age at MI of the first- degree relative (younger 
vs above 50 years of age) (figure 2B–C). In addition, the 
cumulative incidences were repeated with a combined 
outcome of HF diagnosis and fatal MI, but yielded similar 
results as the main analysis with HF as outcome, except that 
family history of a young first- degree relative (≤50 years) 
was no longer significant (figure 3A–C).
Risk of hF stratified according to family history of MI with or 
without hF
Figure 4 presents the crude (figure 4A) and the adjusted 
HR (figure 4B) for family history of MI with HF and 
family history of MI without HF compared with no family 
history, stratified by family relationship. Having a sibling 
with MI complicated by HF was associated with a twofold 
increased risk of HF after first MI compared with cases 
without a sibling with MI (HR 2.05, 95% CI 1.02 to 4.12). 
In addition, having a sibling with MI without HF was asso-
ciated with increased HF risk (HR 1.39, 95% CI 1.05 to 
1.84). However, having a mother or father with MI with or 
without HF was not significantly associated with HF risk 
after first MI. The HRs were repeated with a combined 
outcome of HF diagnosis and fatal MI (figure 5). The HF 
risk associated with family history of MI with or without 
HF was similar regardless of whether the relative with 
MI was young (≤50 years) (online supplementary figure 
1A- B) or old (51–80 years) (online supplementary figure 
2A- B).
dIsCussIOn
In this nationwide study, we investigated the relationship 
between family history of MI with or without HF and the 
risk of developing HF after a first MI in individuals 18–50 
years of age. We demonstrate that having a sibling with 
MI with or without HF was an independent risk factor for 
copyright.
 on A
pril 14, 2020 at A
alborg U
niversity Library. P
rotected by
http://openheart.bm
j.com
/
O
pen H
eart: first published as 10.1136/openhrt-2019-001143 on 24 M
arch 2020. D
ow
nloaded from
 
5Glinge C, et al. Open Heart 2020;7:e001143. doi:10.1136/openhrt-2019-001143
Cardiac risk factors and prevention
Figure 4 (A, B) HRs for heart failure (HF) according to 
family history. Crude (A) and adjusted (B) for sex, age group, 
calendar year group, history of hypertension and diabetes. 
MI, myocardial infarction. *Adjusted for covariates.
Figure 5 (A, B) HRs for heart failure (HF) and fatal 
myocardial infarction (MI) according to family history. Crude 
(A) and adjusted (B) for sex, age group, calendar year 
group, history of hypertension and diabetes. *Adjusted for 
covariates.
developing HF after MI, while a parental family history of 
MI with or without HF was not.
Family aggregation
We found that while sibling history was associated with 
HF risk, parental history was not. Differences in associa-
tion between siblings and parent- offspring could indicate 
that environmental factors shared by siblings are more 
important in determining susceptibility to HF compared 
with inherited (genetic) contributions.15 16 Aggregation 
among siblings suggests that early life familial environ-
mental exposures may increase HF risk, because siblings 
share the family environment at similarly young ages, as 
opposed to children and parents whose ages generally 
differ by two to four decades. In line with the observations 
in this study, previous studies have shown that sibling- 
sibling correlations for most coronary artery disease 
(CAD) risk factors are larger than parent- offspring corre-
lations.15
Our findings contrast to those obtained in two previous 
studies that investigated risk for all- cause HF and demon-
strated that a parental history of HF was associated with 
increased risk of HF in the offspring.8 9 Specifically, data 
from the Framingham Offspring Study (n=2214) showed 
that the occurrence of HF in at least one parent (occur-
ring before 75 years of age) was a significant risk factor 
for HF in the offspring (n=90).8 In subanalyses, parental 
ischaemic HF was also associated with risk of ischaemic HF 
in the offspring (n=11) (HR 2.46, 95% CI 1.10 to 5.49). 
The other is a recent Swedish adoption study of 21 643 
adoptees, of whom 194 developed HF, which found that 
the risk of HF in adoptees who had at least one biological 
parent with HF was 45% higher than in a control group 
with no biological parent suffering from HF.9 In addition, 
this study found no increased risk in individuals with 
adoptive parents with HF. Crucially, these earlier studies 
investigated a smaller group of index cases compared 
with the current analysis. Furthermore, unlike our study 
that focused specifically on HF post- MI in both the index 
cases and the first- degree relatives, these studies (with 
the exception of the subanalysis conducted in a limited 
number of patients in the first study) did not distinguish 
between causes of HF in neither the parents nor the 
offspring. Although CAD is one of the most common 
causes of HF,17 the well- known monogenic forms of HF 
could partly explain the familial aggregation in these 
previous studies, and could underlie, at least in part, the 
findings of parental history as a risk factor for HF in the 
offspring. Additionally, our study has the advantage that 
it was conducted in a nationwide fashion collecting family 
history and relationship data nationwide.
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The genetic architecture underlying susceptibility for 
ischaemic HF is unknown but is believed to comprise 
multiple genetic variants that in combination with envi-
ronmental factors determine an individual’s susceptibility 
to HF. While large- scale genome- wide association studies 
(GWAS) have been successful in identifying common 
genetic variants affecting CAD/MI risk,18 GWAS studies 
for HF are sparse in the literature and compared with 
other complex cardiovascular traits, few common suscep-
tibility genetic variants have been uncovered for HF thus 
far.19 The largest GWAS study on incident HF, conducted 
on 2526 HF events, identified only two single nucleo-
tide polymorphisms.20 The paucity of identified genetic 
susceptibility factors for HF can be due to several factors 
including limited statistical power due to the relatively 
small number of patients with HF that have been studied 
by GWAS so far as well as the heterogeneity in the causes of 
HF in the patients studied. However, this could also point 
to the fact that genetic factors may not play a major role 
in the determination of risk for HF and that other factors, 
such as environmental factors, predominate in the deter-
mination of risk. Our finding that a sibling history of HF 
post- MI is a risk factor for HF whereas a parental history is 
not, supports the latter scenario. On the other hand, our 
data do not exclude the possibility that inherited predis-
position for HF exists but only leads to HF in the pres-
ence of certain environmental factors. As such, genetic 
variants could influence risk for HF through comorbidi-
ties that predispose to HF.21–24 We found that index cases 
with a family history of MI with or without HF were older, 
had higher prevalence of HT and DM, both well- known 
contributing risk factors for MI and HF,25 compared with 
patients with no family history of MI. One could hypoth-
esise that as genetic factors predisposing to comorbidities 
contributing to HF become known, approaches such as 
polygenic risk score analysis will enable the presymptom-
atic identification of susceptible individuals and will allow 
for modification of environmental factors and lifestyle 
adjustments to prevent HF. Nonetheless, family history 
of MI with or without HF, regardless of the nature of 
the various genetic and environmental factors involved, 
serves to identify high- risk individuals and families for 
intervention to prevent HF post- MI.
The recognition of these complexities mentioned 
above should impact the design of future studies seeking 
to identify genetic and environmental risk factors of 
MI- induced HF. Studies should therefore focus on a well- 
defined phenotype (eg, HF following a first MI) instead of 
all- cause HF. Large GWAS of CAD and subsequent events 
are ongoing, and are expected to yield more insights into 
the contribution of heritable risk factors to HF post- MI.26
strengths and limitations
The major strengths of our study include the large and 
unselected nationwide cohort of index cases 18–50 years 
with a first MI, the extensive information on family history, 
comorbidity and pharmacotherapy and the combination 
of detailed data, keeping selection bias at a minimum. 
The main limitations of the study were the time frame in 
which family relations could be determined (the identity 
of parents has been available in Denmark since 1954) and 
the time frame in which the diagnoses were registered 
(1978–2016). In addition, as the parents were born a few 
decades earlier than the offspring and siblings there is 
the possibility that due to diagnostic limitations, HF may 
have gone unrecognised and undiagnosed. Furthermore, 
it is well known that MI occurs up to 10 years later in 
women compared with men,2 and that HF is more likely to 
complicate MI in older persons. This could mean that the 
mother of the index case might have been too young and 
have not yet developed MI. This could possibly lead to an 
underestimation of the number of mothers with MI (with 
or without HF), which may explain the lack of association 
between maternal history of MI (with or without HF) and 
the risk of HF in this study. In addition, the method of 
identifying HF with ICD codes does not identify patients 
with unrecognised HF. Because of this, HF may be under-
diagnosed in our registries. On the other hand, the risk 
of including false- positive patients is limited, as previous 
validation of HF diagnosis by Kümler et al showed a posi-
tive predictive value of 81%.27 Of note, the study reported 
a sensitivity of HF diagnosis of 29%, which indicates a 
large underestimation of the true number of HF cases. 
Additionally, with only a total of 470 index cases with a 
family history of MI with HF and the small numbers of 
affected offspring and siblings, the study might not have 
sufficient statistical power to evaluate the effect on the 
risk of HF post- MI. Other limitations are inherited to the 
observational design of the study and the lack of access 
to clinical data on individual patient characteristics, most 
importantly the type of MI, including the localisation of 
MI, left ventricular ejection fraction and information of 
other important cardiovascular risk factors. These clin-
ical variables may be confounders, because these risk 
factors tend to cluster in families, and therefore might 
have influence on the HF risk after first- time MI in fami-
lies.28 29 On the other hand, it is possible that an ascertain-
ment bias may have occurred with individuals with a posi-
tive sibling history of MI with or without HF as these may 
have a greater likelihood of diagnoses (HT, DM and use 
of statins) than participants with no family history, due 
to increased awareness of the condition by participants. 
Finally, our study is observational and retrospective, thus 
we report associations and not necessarily causal connec-
tions.
COnClusIOn
In this nationwide cohort study of young patients (18–50 
years of age) with a first MI, we found that having a sibling 
with MI with or without HF was associated with increased 
risk of HF post- MI while a parental family history of MI 
with or without HF was not, suggesting that shared envi-
ronmental factors predominate in the determination 
of risk for developing HF. Future studies are necessary 
to validate the kinds of conclusions that can be drawn 
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from this study. This study provides important knowl-
edge for the planning of future studies to untangle risk 
factor relationships and enhancing our understanding of 
the underlying mechanisms of HF after first MI. Better 
understanding of the underlying mechanisms of HF 
post- MI will improve our current risk stratification, diag-
nosis, intervention and prevention.
Author affiliations
1Department of Cardiology, The Heart Centre, Copenhagen University Hospital, 
Rigshospitalet, Copenhagen, Denmark
2Department of Clinical and Experimental Cardiology, Amsterdam UMC, University 
of Amsterdam, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam, The 
Netherlands
3Department of Cardiology, Gentofte Hospital, University of Copenhagen, Hellerup, 
Denmark
4Department of Health, Science and Technology, Aalborg University, Aalborg, 
Denmark
5Department of Cardiology, University of Lund, Lund, Sweden
6The National Institute of Public Health, University of Southern Denmark, 
Copenhagen, Denmark
7The Danish Heart Foundation, Copenhagen, Denmark
8Department of Forensic Medicine, Faculty of Medical Sciences, University of 
Copenhagen, Copenhagen, Denmark
Acknowledgements The authors would like to thank Novo Nordisk Foundation 
and the University Hospital of Copenhagen, Rigshospitalet for financial support.
Contributors CG performed the analysis and drafted the manuscript. RS verified 
the analytical methods. LO, RJ, CB, CT- P, GG and JT- H were involved in planning 
and supervised the work. SR, LK and TE aided in interpreting the results and 
worked on the manuscript. All authors discussed the results, provided critical 
feedback and commented on the manuscript.
Funding This work was supported by the Novo Nordisk Foundation, and CG was 
funded by the University Hospital of Copenhagen, Rigshospitalet, Copenhagen, 
Denmark.
Competing interests None declared.
Patient consent for publication Not required.
ethics approval The study was approved by the Danish Data Protection Agency 
(ref. number: 2007-58-0015/GEH-2014–014 and I- suite number: 02732). In 
Denmark, ethical approval is not required for retrospective register- based studies.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement All data relevant to the study are included in the 
article or uploaded as supplementary information.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCId id
Charlotte Glinge http:// orcid. org/ 0000- 0003- 0406- 256X
RefeRences
 1 Gerber Y, Weston SA, Enriquez- Sarano M, et al. Atherosclerotic 
burden and heart failure after myocardial infarction. JAMA Cardiol 
2016;1:156–62.
 2 Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke 
Statistics—2017 update. Circulation 2017;135:e146–603.
 3 Vasan RS, Xanthakis V, Lyass A, et al. Epidemiology of Left 
Ventricular Systolic Dysfunction and Heart Failure in the Framingham 
Study: An Echocardiographic Study Over 3 Decades. JACC 
Cardiovasc Imaging 2018;11:1–11.
 4 Lewis EF, Velazquez EJ, Solomon SD, et al. Predictors of the first 
heart failure hospitalization in patients who are stable survivors 
of myocardial infarction complicated by pulmonary congestion 
and/or left ventricular dysfunction: a VALIANT study. Eur Heart J 
2008;29:748–56.
 5 Gho JMIH, Postema PG, Conijn M, et al. Heart failure following 
STEMI: a contemporary cohort study of incidence and prognostic 
factors. Open Heart2017;4:e000551.
 6 Verweij N, Eppinga RN, Hagemeijer Y, et al. Identification of 15 novel 
risk loci for coronary artery disease and genetic risk of recurrent 
events, atrial fibrillation and heart failure. Sci Rep 2017;7:2761.
 7 Andersson C, Lyass A, Lin H, et al. Association of genetic variation 
in coronary artery Disease–Related loci with the risk of heart 
failure with preserved versus reduced ejection fraction. Circulation 
2018;137:1290–2.
 8 Lee DS, Pencina MJ, Benjamin EJ, et al. Association of parental 
heart failure with risk of heart failure in offspring. N Engl J Med 
2006;355:138–47.
 9 Lindgren MP, PirouziFard M, Smith JG, et al. A Swedish nationwide 
adoption study of the heritability of heart failure. JAMA Cardiol 
2018;3:703–10.
 10 Lindgren MP, Smith JG, Li X, et al. Sibling risk of hospitalization for 
heart failure – a nationwide study. Int J Cardiol 2016;223:379–84.
 11 Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration 
system as a tool in epidemiology. Eur J Epidemiol 2014;29:541–9.
 12 Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish national 
patient registry: a review of content, data quality, and research 
potential. Clin Epidemiol 2015;7:449–90.
 13 Pottegård A, Schmidt SAJ, Wallach- Kildemoes H, et al. Data 
resource profile: the Danish national prescription registry. Int J 
Epidemiol 2017;46:798–798f.
 14 Rasmussen L, Valentin J, Gesser KM, et al. Validity of the prescriber 
information in the Danish national prescription registry. Basic Clin 
Pharmacol Toxicol 2016;119:376–80.
 15 Knuiman MW, Divitini ML, Welborn TA, et al. Familial correlations, 
cohabitation effects, and heritability for cardiovascular risk factors. 
Ann Epidemiol 1996;6:188–94.
 16 Murabito JM, Pencina MJ, Nam B- H. Sibling cardiovascular disease 
as a risk factor for cardiovascular disease in middle- aged adults. 
JAMA 2005;294:3117–23.
 17 Metra M, Teerlink JR. Heart failure. Lancet 2017;390:1981–95.
 18 Erdmann J, Kessler T, Munoz Venegas L, et al. A decade of genome- 
wide association studies for coronary artery disease: the challenges 
ahead. Cardiovasc Res 2018;114:1241–57.
 19 Buniello A, MacArthur JAL, Cerezo M, et al. The NHGRI- EBI 
GWAS Catalog of published genome- wide association studies, 
targeted arrays and summary statistics 2019. Nucleic Acids Res 
2019;47:D1005–12.
 20 Smith NL, Felix JF, Morrison AC, et al. Association of genome- wide 
variation with the risk of incident heart failure in adults of European 
and African ancestry: a prospective meta- analysis from the cohorts 
for heart and aging research in genomic epidemiology (CHARGE) 
consortium. Circ Cardiovasc Genet 2010;3:256–66.
 21 Warren HR, Evangelou E, Cabrera CP, et al. Genome- wide 
association analysis identifies novel blood pressure loci and 
offers biological insights into cardiovascular risk. Nat Genet 
2017;49:403–15.
 22 Mahajan A, Taliun D, Thurner M, et al. Fine- mapping type 2 diabetes 
loci to single- variant resolution using high- density imputation and 
islet- specific epigenome maps. Nat Genet 2018;50:1505–13.
 23 Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al. Biobank- driven 
genomic discovery yields new insight into atrial fibrillation biology. 
Nat Genet 2018;50:1234–9.
 24 Roselli C, Chaffin MD, Weng L- C, et al. Multi- ethnic genome- wide 
association study for atrial fibrillation. Nat Genet 2018;50:1225–33.
 25 Bozkurt B, Aguilar D, Deswal A, et al. Contributory risk and 
management of comorbidities of hypertension, obesity, diabetes 
mellitus, hyperlipidemia, and metabolic syndrome in chronic heart 
failure: a scientific statement from the American heart association.. 
Circulation 2016;134:e535–78.
 26 Patel RS, Asselbergs FW. The GENIUS- CHD Consortium. Eur Heart 
J 2015;36:2674–6.
 27 Kümler T, Gislason GH, Kirk V, et al. Accuracy of a heart 
failure diagnosis in administrative registers. Eur J Heart Fail 
2008;10:658–60.
 28 Rissanen AM, Nikkilä EA. Aggregation of coronary risk factors in 
families of men with fatal and non- fatal coronary heart disease. Br 
Heart J 1979;42:373–80.
 29 Chen W, Srinivasan SR, Bao W, et al. The magnitude of familial 
associations of cardiovascular risk factor variables between parents 
and offspring are influenced by age: the Bogalusa heart study. Ann 
Epidemiol 2001;11:522–8.
copyright.
 on A
pril 14, 2020 at A
alborg U
niversity Library. P
rotected by
http://openheart.bm
j.com
/
O
pen H
eart: first published as 10.1136/openhrt-2019-001143 on 24 M
arch 2020. D
ow
nloaded from
 
